<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04890782</url>
  </required_header>
  <id_info>
    <org_study_id>KY 2021-072-01</org_study_id>
    <nct_id>NCT04890782</nct_id>
  </id_info>
  <brief_title>Gut Microbiota in Patients With Moyamoya Disease</brief_title>
  <official_title>Gut Microbiota in Patients With Moyamoya Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to find out the association between gut microbiota and moyamoya disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Moyamoya disease (MMD) is a rare cerebrovascular disorder, it is a major cause of stroke in&#xD;
      children and young adults in Japan, Korea, and China, but its pathogenesis is not yet clear.&#xD;
      Dysbiosis of gut microbiota may play a role in the pathological change of MMD. In this&#xD;
      research, the investigators would perform metagenomic sequencing to find the characteristics&#xD;
      of gut microbiota of MMD and to explore the correlations with metabolic, immune, and clinical&#xD;
      symptoms. This research will not only help the understanding of the pathophysiology of MMD,&#xD;
      but also may provide a reference for the selection of clinical treatment options.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diversity analysis of genes and species between MMD patients and the control group</measure>
    <time_frame>Through study completion，eight months.</time_frame>
    <description>Based on the gene and species composition of each sample, the Chao1 and Shannon indexes, as well as the observed OTUs (operational taxonomic units), will be calculated in order to identify the differences in gene and species diversity for each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of differences in intestinal microbiota between MMD patients and the control group</measure>
    <time_frame>Through study completion，eight months.</time_frame>
    <description>The Spearman correlation coefficient between genes will be calculated, and genes with strong correlation will be grouped into one cluster, as a CAG. The abundance of CAGs in each sample will be determined Furthermore, the significantly enriched species in the control and MMD groups will be enumerated for network display.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of functional differences in the intestinal microbiota of MMD patients in comparison to the control group</measure>
    <time_frame>Through study completion，eight months.</time_frame>
    <description>The LEfSe discriminant analysis will be used to screen for significant differences between groups. The dimensionality reduction will be implemented by LDA, and the impact of function difference will be evaluated to obtain the LDA score and identify significantly different functions between groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of metabolites of the intestinal microbiota of MMD patients in comparison to the control group</measure>
    <time_frame>Through study completion，eight months.</time_frame>
    <description>Metabolites of the intestinal microbiota between two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation analysis between gut microbiota in MMD patients and inflammatory cytokines.</measure>
    <time_frame>Through study completion，eight months.</time_frame>
    <description>IL-4,IL-10,IL-13, IFN-α, TGF-β, IL-1,IL-6, IL-17, IFN-β, IFN-γ and TNF-α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation analysis between gut microbiota in MMD patients and neuroimaging markers and cognitive status.</measure>
    <time_frame>Through study completion，eight months.</time_frame>
    <description>MRI: BOLD, DWI, QSM, CUBE, ASL, T1, T2; Cognitive status: Wisdom, Attention, Memory, Linguistic fluency;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The differences of composition of gut microbiota among the genotypes (RNF213 p.R4810K)</measure>
    <time_frame>Through study completion，eight months.</time_frame>
    <description>RNF213 p.R4810K</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Moyamoya Disease</condition>
  <condition>Gut Microbiota</condition>
  <arm_group>
    <arm_group_label>MMD group</arm_group_label>
    <description>Consecutive patients diagnosed with MMD during hospitalization in Beijing Tiantan Hospital, Capital Medical University will be recruited.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control group</arm_group_label>
    <description>Age and sex matched subjects will be invited to join the study as the control.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients diagnosed with MMD during hospitalization in Beijing Tiantan Hospital&#xD;
        will be recruited. Eligibility will be determined through a checklist of inclusion and&#xD;
        exclusion criteria. Control group will be recruited from medical out patient clinic.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of MMD by DSA according to the Japanese guidelines published in 2012,&#xD;
&#xD;
          2. Stenosis or occlusion of the terminal internal carotid and the proximal middle and&#xD;
             anterior cerebral arteries and unilateral or bilateral involvement&#xD;
&#xD;
          3. Age: 2-60 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Moyamoya syndrome,&#xD;
&#xD;
          2. Pregnancy,&#xD;
&#xD;
          3. Evidence of gastrointestinal infection/ inflammation/ obstruction&#xD;
&#xD;
          4. History of partial or total resection of small or large bowel, as well as gut&#xD;
             reanastomosis,&#xD;
&#xD;
          5. Use of antibiotics within 2 weeks prior to symptoms onset,&#xD;
&#xD;
          6. Gastrointestinal malignancy&#xD;
&#xD;
          7. Any hospitalization within 3 months before recruitment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Zhang, MD</last_name>
    <phone>13801121292</phone>
    <email>zhangdong0660@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peicong Ge, MD</last_name>
    <phone>15010545727</phone>
    <email>gepeicong@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Zhang, MD</last_name>
      <phone>13801121292</phone>
      <email>zhangdong0660@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Peicong Ge, MD</last_name>
      <phone>15010545727</phone>
      <email>gepeicong@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moyamoya Disease</keyword>
  <keyword>Microbiome</keyword>
  <keyword>RNF213 p.R4810K</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moyamoya Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

